vs
NovaBay Pharmaceuticals, Inc.（NBY）与Rithm Property Trust Inc.（RPT）财务数据对比。点击上方公司名可切换其他公司
NovaBay Pharmaceuticals, Inc.的季度营收约是Rithm Property Trust Inc.的1.4倍（$4.8M vs $3.4M），Rithm Property Trust Inc.净利率更高（95.4% vs -25.5%，领先120.9%），NovaBay Pharmaceuticals, Inc.同比增速更快（126.1% vs -39.7%），过去两年NovaBay Pharmaceuticals, Inc.的营收复合增速更高（42.5% vs -43.2%）
诺瓦湾制药（NovaBay Pharmaceuticals）是一家总部位于美国加利福尼亚州埃默里维尔的临床阶段生物制药企业，聚焦眼科护理产品的研发与商业化。其核心产品Avenova获美国FDA批准，可用于睑缘炎疗程中的眼睑睫毛清洁，另一产品NeutroPhase则可用于坏死性筋膜炎的治疗。
Rithm Property Trust Inc.旗下的里思资本是一家总部位于纽约的美国投资管理公司，核心业务聚焦于房地产投资及另类投资领域，是该赛道颇具影响力的专业投资机构。
NBY vs RPT — 直观对比
营收规模更大
NBY
是对方的1.4倍
$3.4M
营收增速更快
NBY
高出165.8%
-39.7%
净利率更高
RPT
高出120.9%
-25.5%
两年增速更快
NBY
近两年复合增速
-43.2%
损益表 — Q4 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $4.8M | $3.4M |
| 净利润 | $-1.2M | $3.2M |
| 毛利率 | 65.2% | — |
| 营业利润率 | -37.2% | 99.6% |
| 净利率 | -25.5% | 95.4% |
| 营收同比 | 126.1% | -39.7% |
| 净利润同比 | 70.5% | 11.2% |
| 每股收益（稀释后） | — | $-0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NBYRPT
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $4.2M | ||
| Q1 25 | — | $249.0K | ||
| Q4 24 | $4.8M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $2.6M | — |
净利润NBYRPT
| Q4 25 | — | $3.2M | ||
| Q3 25 | — | $-273.0K | ||
| Q2 25 | — | $1.9M | ||
| Q1 25 | — | $-3.4M | ||
| Q4 24 | $-1.2M | — | ||
| Q3 24 | $-1.2M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-3.2M | — |
毛利率NBYRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 65.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 66.3% | — | ||
| Q1 24 | 68.2% | — |
营业利润率NBYRPT
| Q4 25 | — | 99.6% | ||
| Q3 25 | — | -6.2% | ||
| Q2 25 | — | 45.7% | ||
| Q1 25 | — | -1416.5% | ||
| Q4 24 | -37.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -67.4% | — | ||
| Q1 24 | -87.1% | — |
净利率NBYRPT
| Q4 25 | — | 95.4% | ||
| Q3 25 | — | -6.8% | ||
| Q2 25 | — | 45.1% | ||
| Q1 25 | — | -1363.1% | ||
| Q4 24 | -25.5% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -66.0% | — | ||
| Q1 24 | -122.2% | — |
每股收益（稀释后）NBYRPT
| Q4 25 | — | $-0.26 | ||
| Q3 25 | — | $-0.03 | ||
| Q2 25 | — | $0.01 | ||
| Q1 25 | — | $-0.08 | ||
| Q4 24 | — | — | ||
| Q3 24 | $-1.92 | — | ||
| Q2 24 | $-1.37 | — | ||
| Q1 24 | $-29.95 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $430.0K | $79.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-129.0K | $291.6M |
| 总资产 | $3.4M | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资NBYRPT
| Q4 25 | — | $79.3M | ||
| Q3 25 | — | $81.4M | ||
| Q2 25 | — | $98.6M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | $430.0K | — | ||
| Q3 24 | $776.0K | — | ||
| Q2 24 | $751.0K | — | ||
| Q1 24 | $1.8M | — |
股东权益NBYRPT
| Q4 25 | — | $291.6M | ||
| Q3 25 | — | $291.7M | ||
| Q2 25 | — | $294.7M | ||
| Q1 25 | — | $296.1M | ||
| Q4 24 | $-129.0K | — | ||
| Q3 24 | $1.1M | — | ||
| Q2 24 | $-617.0K | — | ||
| Q1 24 | $160.0K | — |
总资产NBYRPT
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $1.0B | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $1.0B | ||
| Q4 24 | $3.4M | — | ||
| Q3 24 | $3.9M | — | ||
| Q2 24 | $3.9M | — | ||
| Q1 24 | $5.4M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $-8.3M |
| 自由现金流经营现金流 - 资本支出 | $-1.7M | — |
| 自由现金流率自由现金流/营收 | -35.4% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | -2.56× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流NBYRPT
| Q4 25 | — | $-8.3M | ||
| Q3 25 | — | $-5.8M | ||
| Q2 25 | — | $-25.0K | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-2.4M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-2.0M | — |
自由现金流NBYRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-2.0M | — |
自由现金流率NBYRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -35.4% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -75.3% | — |
资本支出强度NBYRPT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.1% | — |
现金转化率NBYRPT
| Q4 25 | — | -2.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.01× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NBY
| Other | $2.4M | 51% |
| Total Product Revenue | $2.3M | 49% |
RPT
暂无分部数据
